摘要
目标:流行病学数据表明非甾体类抗炎药(NSAIDs)可以预防阿尔茨海默病(AD)。不幸的是,最近的试验未能提供令人信服的神经保护证据。关于为什么NSAIDs有效性尚不确定的讨论正在进行中。可能的解释包括在患者出现AD或认知功能下降症状之前应提供NSAIDs和其他可能的疾病缓解药物。另外,用于神经保护的NSAID目标还不清楚。已提出COX依赖性和独立机制,包括裂解淀粉样蛋白前体蛋白(APP)并产生淀粉样蛋白β肽(Aβ)的γ-分泌酶。 方法:我们已经提出了基于抑制线粒体Ca 2+超载的NSAID的神经保护机制。 Aβ寡聚体促进Ca2 +内流和线粒体Ca2 +超载导致神经元细胞死亡。包括布洛芬,舒林酸,吲哚美辛和Rflurbiprofen在内的几种非特异性NSAIDs在低μM范围内使线粒体去极化,并防止由Aβ寡聚体和/或N-甲基-D-天冬氨酸(NMDA)诱导的线粒体Ca2 +超载。然而,在较高的浓度下,NSAIDs可能会破坏导致细胞死亡的线粒体潜能(ΔΨ)。 结果:因此,这种机制可能解释低浓度的神经保护作用和更大剂量的损伤,从而为有希望的试验的失败提供线索。对于将来的试验,应考虑降低NSAID浓度和/或具有较大动态范围的替代化合物以提供针对AD的神经保护的确切证据
关键词: 阿尔茨海默氏病,非甾体抗炎药,钙,线粒体,淀粉样蛋白β寡聚体,N-甲基-D-天冬氨酸。
Current Alzheimer Research
Title:Is it All Said for NSAIDs in Alzheimer’s Disease? Role of Mitochondrial Calcium Uptake
Volume: 15 Issue: 6
关键词: 阿尔茨海默氏病,非甾体抗炎药,钙,线粒体,淀粉样蛋白β寡聚体,N-甲基-D-天冬氨酸。
摘要: Objectives: Epidemiological data suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer's disease (AD). Unfortunately, recent trials have failed in providing compelling evidence of neuroprotection. Discussion as to why NSAIDs effectivity is uncertain is ongoing. Possible explanations include the view that NSAIDs and other possible disease-modifying drugs should be provided before the patients develop symptoms of AD or cognitive decline. In addition, NSAID targets for neuroprotection are unclear. Both COX-dependent and independent mechanisms have been proposed, including γ-secretase that cleaves the amyloid precursor protein (APP) and yields amyloid β peptide (Aβ).
Methods: We have proposed a neuroprotection mechanism for NSAIDs based on inhibition of mitochondrial Ca2+ overload. Aβ oligomers promote Ca2+ influx and mitochondrial Ca2+ overload leading to neuron cell death. Several non-specific NSAIDs including ibuprofen, sulindac, indomethacin and Rflurbiprofen depolarize mitochondria in the low µM range and prevent mitochondrial Ca2+ overload induced by Aβ oligomers and/or N-methyl-D-aspartate (NMDA). However, at larger concentrations, NSAIDs may collapse mitochondrial potential (ΔΨ) leading to cell death.
Results: Accordingly, this mechanism may explain neuroprotection at low concentrations and damage at larger doses, thus providing clues on the failure of promising trials. Perhaps lower NSAID concentrations and/or alternative compounds with larger dynamic ranges should be considered for future trials to provide definitive evidence of neuroprotection against AD.
Export Options
About this article
Cite this article as:
Is it All Said for NSAIDs in Alzheimer’s Disease? Role of Mitochondrial Calcium Uptake, Current Alzheimer Research 2018; 15 (6) . https://dx.doi.org/10.2174/1567205015666171227154016
DOI https://dx.doi.org/10.2174/1567205015666171227154016 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interactions of VDAC with Proteins Involved in Neurodegenerative Aggregation: An Opportunity for Advancement on Therapeutic Molecules
Current Medicinal Chemistry Biochemical and Therapeutic Effects of Antioxidants in the Treatment of Alzheimers Disease, Parkinsons Disease, and Amyotrophic Lateral Sclerosis
Current Drug Targets - CNS & Neurological Disorders Applications of Artificial Neural Networks in Medical Science
Current Clinical Pharmacology Renal Biopsy Research with Implications for Therapy of Glomerulonephritis
Current Drug Therapy Relations of Magnesium Intake with Metabolic Risk Factors and Risks of Type 2 Diabetes, Hypertension, and Cardiovascular Disease: A Critical Appraisal
Current Nutrition & Food Science A Link Between Brain Insulin Resistance and Cognitive Dysfunctions: Targeting Ca2+/cAMP Signalling
Central Nervous System Agents in Medicinal Chemistry α-Synuclein Ubiquitination and Novel Therapeutic Targets for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Current Advancements in Aβ Luminescent Probes and Inhibitors of Aβ Aggregation
Current Alzheimer Research Pharmacogenetics and Pharmagenomics, Trends in Normal and Pathological Aging Studies: Focus on p53
Current Pharmaceutical Design Helminth Infections and Cardiovascular Diseases: Toxocara Species is Contributing to the Disease
Current Cardiology Reviews <i>In-silico</i> Studies and Biological Activity of Potential BACE-1 Inhibitors
Combinatorial Chemistry & High Throughput Screening Bridging Neurocognitive Aging and Disease Modification: Targeting Functional Mechanisms of Memory Impairment
Current Alzheimer Research Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer’s Disease
Current Pharmaceutical Design EDITORIAL (Thematic Issue: Preeclampsia and Modern Approaches to Diagnosis and Therapy)
Current Women`s Health Reviews Intracellular Amyloid β-Protein and Its Associated Molecules in the Pathogenesis of Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Prevalence of Analgesic Use and Pain in People with and without Dementia or Cognitive Impairment in Aged Care Facilities: A Systematic Review and Meta-Analysis
Current Clinical Pharmacology Secondary Prevention of Atherothrombotic Cerebrovascular Events
Current Vascular Pharmacology Preventive and Protective Roles of Dietary Nrf2 Activators Against Central Nervous System Diseases
CNS & Neurological Disorders - Drug Targets Definition of Genes and Paths Involved in Alzheimers Disease: Using Gene Expression Profiles and Chemical Genetics at the Mouse Brain Level
Current Genomics